Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is China Biotech Services Holdings Days Payable?
China Biotech Services HoldingsHKSE:08037 -1.54%19 Days Payable is 129.54 as of Dec. 2025, which is 173% above its 10-year median of 47.50. GuruFocus rates HKSE:08037 with a GF Score™ of 19/100 and a GF Value™ of HK$0.27 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks better than 61.58% on this metric.
The historical rank and industry rank for China Biotech Services Holdings's Days Payable or its related term are showing as below:
HKSE:08037'
s Days Payable Range Over the Past 10 Years
Min: 27.52 Med: 47.5 Max: 218.01
Current: 90.92
During the past 13 years, China Biotech Services Holdings's highest Days Payable was 218.01. The lowest was 27.52. And the median was 47.50.
HKSE:08037's Days Payable is ranked better than 61.58% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs HKSE:08037: 90.92
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings Days Payable Chart
HKSE:08037 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's Days Payable falls into.
China Biotech Services Holdings Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings (HKSE:08037) has a Days Payable of 129.54 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Biotech Services Holdings and its competitors. This is 173% above median its historical median of 47.50. Over the past decade, China Biotech Services Holdings' Days Payable has ranged from 27.52 to 218.01. According to the industry distribution chart, China Biotech Services Holdings ranks #73 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 38.4%.
Is China Biotech Services Holdings' Days Payable too high?
China Biotech Services Holdings' current Days Payable of 129.54 is 173% above median its 10-year median of 47.50. Over the past 10 years, this metric has ranged from a low of 27.52 to a high of 218.01. The Medical Diagnostics & Research industry median Days Payable is 64.64. China Biotech Services Holdings' value of 129.54 is 100.4% above this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #73 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #73 out of 190 companies for Days Payable. This puts China Biotech Services Holdings in the upper half of its industry. The industry median Days Payable is 64.64. China Biotech Services Holdings' value of 129.54 is 100.4% above this benchmark. Historically, China Biotech Services Holdings' own Days Payable has ranged from 27.52 to 218.01 over the past decade. While the company's 10-year median is 47.50 vs. the industry median of 64.64, China Biotech Services Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current Days Payable of 129.54 is 100.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Days Payable is 129.54, which is 173% above median its own 10-year median of 47.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Days Payable is 129.54, which is 173% above median its 10-year median of 47.50 and 100.4% above the Medical Diagnostics & Research industry median of 64.64. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Days Payable is 129.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
Days Payable: 129.54 (173% above median its 10-year median of 47.50)
GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
Industry Position: 100.4% above the Medical Diagnostics & Research median (#73 of 190)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Business Description
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
